ABSTRACT
Three types of sorbents were developed for the specific removal of atherogenic apoB-containing low-density lipoprotein (LDL) and lipoprotein LDL (a) (Lp[a]) from human plasma. Two sorbents contained monospecific sheep polyclonal or mouse monoclonal antibodies against human apoprotein B-100. The third one was intended for specific removal of Lp(a) and contains sheep antibodies against human Lp(a). Thirty patients were treated for up to 9 years by LDL apheresis with anti-LDL immunosorbents. A pilot study of Lp(a) apheresis with 3 patients was conducted during 3 years. The results showed that extracorporeal immunosorption is safe and effective for lowering LDL and Lp(a). These procedures may be used both for metabolic investigations and for studies on possible regression of atherosclerosis.
Subject(s)
Apolipoproteins B/blood , Blood Component Removal , Hypercholesterolemia/therapy , Immunosorbents , Lipoprotein(a)/blood , Lipoproteins, LDL/blood , Adolescent , Adult , Animals , Antibodies/immunology , Antibodies/metabolism , Apolipoproteins B/immunology , Child , Coronary Angiography , Enzyme-Linked Immunosorbent Assay , Female , Fibrinogen/analysis , Humans , Immunosorbent Techniques , Immunosorbents/immunology , Immunosorbents/therapeutic use , Longitudinal Studies , Male , Mice , Middle Aged , Pilot Projects , Plasminogen/analysis , SheepABSTRACT
Sheep polyclonal anti-lipoprotein (a) [anti-Lp(a)] antibodies were used for immunosorbent preparation. The ability of the selective removal of Lp(a) from human plasma by this sorbent was demonstrated in an in vitro study. The material desorbated from the anti-Lp(a) column by acid pH has immunochemical properties identical to those of Lp(a) isolated by ordinary methods. The binding capacity of anti-Lp(a) sorbent is 3 mg Lp(a) per 1 ml gel. Immunosorbent prepared in this study was reusable. It is suggested that anti-Lp(a) immunosorbent may be applied for clinical plasma adsorption therapy for the Lp(a)-apheresis procedure, especially for patients with high Lp(a) concentration in blood and with stenosis in coronary and cerebral arteries.
Subject(s)
Immunosorbent Techniques , Immunosorbents , Lipoproteins/blood , Animals , Humans , Immunoelectrophoresis , In Vitro Techniques , Lipoprotein(a) , Lipoproteins/immunology , SheepABSTRACT
Low density lipoprotein (LDL) (1,03-1,05 g/ml) was utilized as antigen to obtain polyclonal (PcAb) and monoclonal (McAb) antibodies. Immunosorbents capable of selective removing LDL from human plasma were developed on the basis of the antibodies preparation. The sorbents called "Immunoliposorber PcAb" and "Immunoliposorber McAb" are currently undergoing clinical trials in the USSR Cardiology Research Center, Acad. of Med. Sciences.
